Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INVA with free AI briefings, catalyst countdowns, and dilution alerts.

INVA · Innoviva, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1B Cash on Hand
CF+ Cash Runway
Follow INVA by email Get an email when INVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INVA, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Trimethoprim-Sulfamethoxazole Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting
Sulbactam Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting
Moxifloxacin Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting
IV Eravacycline 1.5mg/kg Complicated Intra-abdominal Infections (cIAI) Phase 2 · NCT06794541 Recruiting
Imipenem Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting
Ethambutol Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting
Ceftriaxone Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting
Bedaquiline Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting
Azithromcyin Mycobacterium Abscessus Pulmonary Disease Phase 2 · NCT07485010 Not yet recruiting

Also used in these trials (approved or third-party drugs, not INVA's own candidates): Angiotensin Ii, Ceftobiprole Medocaril Sodium, Amikacin, Tigecycline, Rifabutin, Linezolid, Doxycycline, Clofazimine, Clarithromycin, Cefoxitin Sodium, Amoxicillin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INVA holds $1.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INVA files for a raise →

👥 Who Owns INVA

Insiders 9.3% Other 5%+ holders 78% Institutions (432 holders) 12.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Innoviva, Inc. 5%+ holder (13D) 55,467,459 78.03% 2026-05-12
BlackRock, Inc. Institution (13G, 5%+) 11,138,961 15.67% 2026-09-30
Alexander J Denner
10% owner
Insider 5,658,705 7.96% 2025-03-04
Dimensional Fund Advisors LP Institution (13G, 5%+) 4,360,401 6.13% 2025-12-31
Vanguard Portfolio Management Institution (13G, 5%+) 4,288,063 6.03% 2026-03-31
Renaissance Technologies LLC Institution (13G, 5%+) 4,210,172 5.92% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 3,704,185 5.21% 2026-06-30
Pavel Raifeld
Chief Executive Officer, Director · +1.38M options
Insider 284,799 0.40% 2026-08-20
Jules Haimovitz
Director · +20,000 options
Insider 152,692 0.21% 2026-05-04
Mark DiPaolo
Director · +20,000 options
Insider 140,492 0.20% 2026-05-04
Sarah J. Schlesinger
Director · +20,000 options
Insider 140,492 0.20% 2026-05-04
Stephen Basso
Chief Financial Officer · +370,480 options
Insider 88,013 0.12% 2026-08-20

Share count 71,081,477 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-11-05 NUZOLVENCE® (zoliflodacin) NDA +4.2% +0.4% +20.7%

Browse all historical PDUFA outcomes →

Get the full INVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.